Menlo Ventures closed $3 billion across two new funds on June 23, the largest capital raise in the firm's 50-year history, per the launch coverage. The pool is explicitly AI-focused, with Menlo signaling deployment across "production AI" categories: systems that make decisions, route patients, govern agents, search the live web for machines. The firm led the Assort Health $120 million Series C announced the same day, which gives a read on the deployment pace they are planning.
The size and the cadence together tell you what Menlo thinks AI Series A and B multiples will look like for the next 36 months. At $3 billion of dry powder on a typical 3-4 year deployment window, the firm needs to put roughly $750 million to $1 billion a year into priced rounds. At current Series A medians ($50 million pre-money for an AI-native company per recent data), that is roughly 20-30 lead positions a year if Menlo writes $30-50 million checks. The size assumes the current Series A environment continues, with no compression baked in.
The cap-table reading for founders is that the venture market just signaled it has more capital than it has reasonable AI investments to spend it on. That mismatch always pushes valuations up first and discipline last. For founders raising in the next 18 months, the price will be there. The risk is the round size growing past what the company actually needs, which is the pattern that historically produces dilution founders regret two rounds later. Take the right round size for the milestones, not the round size the market will write.
Bottom Line
Menlo's $3 billion is the loudest signal yet that the venture market sees no near-term ceiling on AI Series A and B valuations. For founders that means the price is available. The discipline has to come from inside the company.